T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

http://www.wikidata.org/entity/Q37272020

about

Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street Adoptive T-cell therapy for Leukemia Novel therapeutic options in Acute Myeloid Leukemia Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.Driving CAR T-cells forward Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimeric antigen receptor T cell therapy in AML: How close are we?Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells Seatbelts in CAR therapy: How Safe Are CARS?T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities Immunotherapy in pediatric malignancies: current status and future perspectives Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

P2860

Q26775720-16BC9725-FF97-4E7B-8693-F3CE7FC70846 Q26781328-26598BE6-EA2F-453A-8711-473151C82701 Q26795540-5200529E-84FD-4490-B1DD-333FDEB3895F Q26799357-51F08124-12EC-4D0A-9C17-B2C335B8E11F Q27006934-97AC15EB-0CFA-4F77-8BE6-5C6D9CD30305 Q28069889-221A8B4D-9E75-45DF-85FB-D0F2613A8ECF Q28075654-76791316-73B6-4FD4-B130-D34105E4E509 Q28079823-3D14ABB9-DF5A-4B2F-B060-A93DEDD1C360 Q28553650-90505AE8-6828-4B92-B4BF-770DAAFE9608 Q28554677-0FB37AED-C6E4-4192-AEBC-4E8F86F8A1F3 Q30637447-4E79FEA1-A062-4701-B4F1-5838E42F94E5 Q30827633-AC7ADAF7-09E1-426E-859F-ED738A8FA023 Q33415505-C71D47A8-52B2-4D0C-8E15-542C225FF315 Q34046505-6165257F-CA3B-4F4E-A2B7-8D8C47379910 Q34232877-9A910801-7DFD-4ABA-AB9F-8810D24B3AC9 Q34517676-AE6BBA8A-F2F5-4B4F-9B51-2A9054DB630B Q34545962-405D3A97-12D4-496E-8615-EB1519036F60 Q34674124-881A02D5-6DAC-4E37-BCE3-57A91AF54A7D Q35146288-D9B8CC72-B728-4BEB-9C2A-D0D537495D21 Q35399080-4FA3D800-7A30-4BC2-A1CA-6E501FDA82F2 Q35546759-D11442C2-7764-4232-A5EC-E475E359F39C Q35634680-F2C44AD0-61C7-4B9E-8D73-7B84DC847334 Q35661999-8B7ECB54-D7E2-438C-9BD7-BE154005576B Q35818365-E6576A69-D0CA-42F8-98DF-2A2FF1B87E8D Q35899277-723BA8CE-43BD-46A6-8656-7AC1A263C20B Q36219592-46640B25-B9C5-4107-AFB8-4931C962DA38 Q36279306-E3787566-D3BD-42BE-B2DC-06730555BF19 Q36443107-F1B3B07B-B30C-4479-9931-600B996FE4D2 Q36447553-AA3137A1-C988-4A80-AFA5-89CE913C1AC6 Q36691818-D9250EDE-4072-4103-B795-2468CE765239 Q36777093-BB63C27B-B504-450B-8578-143499521662 Q36957716-82C031D0-ABC3-4063-9D46-D4DD91168FBF Q37587956-BC9BD655-492B-400B-8668-D46A77595BAE Q37609801-BE88AA8C-E012-439A-9DE4-C02DA4367B85 Q37624593-8DE9202F-A6AC-4690-BA6B-279B1D189679 Q37643136-6E812F88-BE13-41F5-B8C2-6A35F1EF772F Q37687827-E43639AC-5BA7-445A-AECE-58A84AC8391D Q37697847-A809BC7B-574E-4F9F-BC93-467855221F4A Q37723469-7158B6A8-E251-42A0-9C39-B12960EDB7FC Q38186870-3B819358-B317-4366-9B9F-CEC8B0A3798E

P2860

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.

http://www.wikidata.org/entity/Q37272020

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@en

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@nl

type

label

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@en

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@nl

prefLabel

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@en

T cells expressing CD123-speci ...... human acute myeloid leukemia.

@nl

P1433

Q37272020-E2B01AAE-0CD8-41D8-A7E4-28DDD1706940

P1476

Q37272020-FAEE264C-B5D2-4DDC-9C7F-71465BA52149

P2093

Q37272020-15C64037-1FFF-4259-83FA-D10CF6B6BB7D

Q37272020-1FB39725-DA2D-43C2-823F-AF47969CD6DB

Q37272020-22311379-BA26-4AD9-9F5F-8D806F49AD16

Q37272020-34E27D78-2C3F-4B25-8ADC-8ABB9FB16DDB

Q37272020-40184F5F-DFA3-4FC5-83F2-17B443F173BB

Q37272020-5F110A86-F175-4C68-8056-2F3F3B36954E

Q37272020-6237AD2E-0925-4B16-874C-F97FBED8FD1C

Q37272020-699972C2-C581-4E2D-8455-AA07EE15F47E

Q37272020-7A80CAE6-8C36-48C0-9B31-C0F09060890B

Q37272020-A0F3C7A7-F246-4C54-9AB9-C85DEAE70D31

P2860

Q37272020-0A3F25F4-3381-4A52-8EDA-E6C97C6F0C5C

Q37272020-0CE08180-99E1-46D6-ABDF-AD099AC141A3

Q37272020-0DF3F49A-39A1-4F23-B5BA-C4287BC9B8F1

Q37272020-0E52EB3B-097A-4C5E-B0AC-4BAA03EA4E3E

Q37272020-14228FE7-93D3-48EA-9322-87D6A1336F3F

Q37272020-1475F716-1F13-44B9-9D45-44BE940752F7

Q37272020-1A9769AA-E38C-494A-8E95-9F7B994FAB1F

Q37272020-1C835F38-11E7-4894-BED3-CDC40BD91198

Q37272020-1E94CFE7-A329-4673-BDB0-A96D50DB0746

Q37272020-2A275114-5FBA-4C88-8491-68BF57703EB7

P304

Q37272020-62AEC8FC-05D5-4298-B8B4-FBAC8D3CA071

P31

Q37272020-6D5D066F-2887-45B0-9568-56F41E7B7D65

P356

Q37272020-AAE73C81-FDC2-4447-B3E0-D9998AF5B225

P407

Q37272020-A9C7EDCF-D357-41F2-A6C3-4D5FDB8721C2

P433

Q37272020-8EF7E488-397B-47AB-9F31-1D2EFC6499D3

P478

Q37272020-767213E4-4D61-4B4C-BA80-05615427721A

P50

Q37272020-B0B308E7-3516-46EE-98A4-BAF2322A718F

P577

Q37272020-401DD00B-7094-44A5-97AA-735CA2FDBBF0

P5875

Q37272020-A26A7CAC-C57B-45C5-9122-AE855C777F41

P698

Q37272020-88A52E17-FB4C-42D6-B53A-3350AD7F230C

P921

Q37272020-60BA15E8-4EA3-4EFA-ACD5-5741A4BE11A7

P932

Q37272020-C9C9BBEE-BB0D-4484-A410-3EEFF773B029

P356

BLOOD-2012-12-474056

P1433

P1476

T cells expressing CD123-speci ...... t human acute myeloid leukemia

@en

P2093

Armen Mardiros

http://www.w3.org/2001/XMLSchema#string

Brenda Aguilar

http://www.w3.org/2001/XMLSchema#string

Brenda Chang

http://www.w3.org/2001/XMLSchema#string

Cedric Dos Santos

http://www.w3.org/2001/XMLSchema#string

Julie R Ostberg

http://www.w3.org/2001/XMLSchema#string

L Elizabeth Budde

http://www.w3.org/2001/XMLSchema#string

Lauren Hoffman

http://www.w3.org/2001/XMLSchema#string

Mahesh Jonnalagadda

http://www.w3.org/2001/XMLSchema#string

Michael C Jensen

http://www.w3.org/2001/XMLSchema#string

Ravi Bhatia

http://www.w3.org/2001/XMLSchema#string

P2860

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Recent advance in antigen-specific immunotherapy for acute myeloid leukemia

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

A human memory T cell subset with stem cell-like properties

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P304

3138-3148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-12-474056

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Christine E Brown

P577

2013-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256541002

http://www.w3.org/2001/XMLSchema#string

P698

24030378

http://www.w3.org/2001/XMLSchema#string

P921

P932

3814731

http://www.w3.org/2001/XMLSchema#string